NCT03481998: A Study of SHR6390 + Letrozole for First-Line Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer

NCT03481998
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 75 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous system metastases
https://ClinicalTrials.gov/show/NCT03481998

Comments are closed.

Up ↑